Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xaliproden for Oxaliplatin Neurotoxicity in MCRC
NCT00272051Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2002
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing Xaliproden + FOLFOX4 with Placebo + FOLFOX4 (2 arms). Primary endpoints: Occurrence of Grade 3-4 Peripheral Sensory Neuropathy and Objective Response Rate. Started Jul 2002; status: completed.
02
Drugs
xaliproden
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT00272051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00272051.